All In Biotech

Drug Trial Radar · NCT01836705

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors

Last checked: Nov 21, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

May 2013

Primary completion

Nov 2013

Study completion May 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors. Secondary Objectives: * To assess the effect of SAR302503 administered as 14-day repeated doses on heart rate (HR), QT, QTcB, and QTcN, PR and QRS compared to placebo. * To assess the clinical and laboratory safety of SAR302503 * To document the plasma concentrations of SAR302503 at the time of ECG investigation. * To explore the Pharmacokinetic/Pharmacodynamic relationship between SAR302503 concentration and QTcF * To explore antitumor activity

Conditions

  • Neoplasm Malignant

Interventions

  • SAR302503 (TG101348)Drug

    Pharmaceutical form:capsule Route of administration: oral

  • Placebo SAR302503Drug

    Pharmaceutical form:capsule Route of administration: oral

  • PanolosetronDrug

    Pharmaceutical form:solution Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QTc Friderica (QTcF) parameterTime frame: 16 days

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840003

    Los Angeles, California

  • Investigational Site Number 840007

    Augusta, Georgia

  • Investigational Site Number 840002

    Detroit, Michigan

  • Investigational Site Number 840001

    St Louis, Missouri

  • Investigational Site Number 840004

    Cincinnati, Ohio

  • Investigational Site Number 840005

    Philadelphia, Pennsylvania

  • Investigational Site Number 840006

    San Antonio, Texas

  • Investigational Site Number 840008

    San Antonio, Texas

  • Investigational Site Number 056001

    Brussels, Belgium

  • Investigational Site Number 056002

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.